FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 09:04:36 24/05/2024 pm IST | ||
| 5.18 EUR | +7.47% |
|
| Current month | +180.00% | ||
| 1 month | +145.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 5.18 | +7.47% |
| 23/24/23 | 4.82 | +9.05% |
| 22/24/22 | 4.42 | +9.68% |
| 21/24/21 | 4.03 | -10.24% |
| 20/24/20 | 4.49 | +7.67% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 09:04 pm IST
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SN7D86 |
| ISIN | DE000SN7D862 |
| Date issued | 28/07/2022 |
| Strike | 288.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.82 € |
|---|---|
| Lowest since issue | 1.26 € |
| Spread | 0.14 € |
| Spread % | 2.60% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
